Literature DB >> 29033046

Eschar removal by bromelain based enzymatic debridement (Nexobrid®) in burns: An European consensus.

Christoph Hirche1, Antonella Citterio2, Henk Hoeksema3, Ján Koller4, Martina Lehner5, José Ramón Martinez6, Stan Monstrey3, Alexandra Murray7, Jan A Plock8, Frank Sander9, Alexandra Schulz10, Benjamin Ziegler11, Ulrich Kneser11.   

Abstract

Early debridement and/or eschar removal is regarded as a significant step in the treatment of deep partial and full thickness burns. It aims to control wound bioburden and allows early wound closure by conservative treatment or skin grafting. Preservation of viable dermis accompanied by early wound closure, is regarded as a necessary step to reduce scar related complication, e.g. functional limitations and/or unaesthetic scar formation. Aside from the classical techniques of surgical excision as tangential excision for eschar removal, hydro-surgery, maggot therapy, laser, enzymatic debridement have been described as additional techniques in the burn surgeon's armamentarium. It is widely accepted that early eschar removal within 72h improves the outcome of burn wound treatment by reducing bacterial wound colonization, infection and length of hospital stay. In contrast, the right technique for eschar removal is still a matter of debate. There is increasing evidence that enzymatic debridement is a powerful tool to remove eschar in burn wounds, reducing blood loss, the need for autologous skin grafting and the number of wounds requiring surgical excision. In order to assess the role and clinical advantages of enzymatic debridement by a mixture of proteolytic enzymes enriched in Bromelain (Nexobrid®) beyond the scope of the literature and in view of users' experience, a European Consensus Meeting was scheduled. The aim was to provide statements for application, based on the mutual experience of applying enzymatic debridement in more than 500 adult and pediatric patients by the consensus panelists. Issues to be addressed were: indications, pain management and anesthesia, timing of application, technique of application, after-intervention care, skin grafting after enzymatic debridement, blood loss, training strategies and learning curve and areas of future research needs. Sixty-eight (68) consensus statements were provided for the use of enzymatic debridement. The degree of consensus was remarkably high, with a unanimous consensus in 88.2% of statements, and lowest degree of consensus of 70% in only 3 statements. This consensus document may serve as preliminary guideline for the use of enzymatic debridement with user-oriented recommendations until further evidence and systematic guidelines are available.
Copyright © 2017 Elsevier Ltd and ISBI. All rights reserved.

Entities:  

Keywords:  Burn; Consensus; Enzymatic debridement; Eschar removal; Nexobrid

Mesh:

Substances:

Year:  2017        PMID: 29033046     DOI: 10.1016/j.burns.2017.07.025

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  16 in total

1.  Procedural sedation and analgesia during enzymatic debridement of burn patients.

Authors:  R Galeiras; M Mourelo; S Pértega; M E López; I Esmorís
Journal:  Ann Burns Fire Disasters       Date:  2018-09-30

2.  Does Platelet-Rich Fibrin Enhance Healing Of Burn Wounds? Our First Experiences And Main Pitfalls.

Authors:  A Schulz; J L Schiefer; P C Fuchs; C H Kanho; N Nourah; W Heitzmann
Journal:  Ann Burns Fire Disasters       Date:  2021-03-31

3.  Selective Enzymatic Debridement For The Management Of Acute Upper Limb Burns.

Authors:  M Cherubino; L Valdatta; T Baroni; I Pellegatta; F Tamborini; L Garutti; P Di Summa; R Adani
Journal:  Ann Burns Fire Disasters       Date:  2021-12-31

Review 4.  Burns in Israel: Etiologic, Demographic, and Clinical trends-A 9-Year Updated Comprehensive Study, 2004-2010 versus 2011-2019.

Authors:  Irit Cohen-Manheim; Moti Harats; Sharon Goldman; Dmitry Beylin; Josef Haik; Moran Bodas; Adi Givon; Rachel Kornhaber; Yehiel Hayun; Michelle Cleary; Daniel Hilewitz; Ariel Tessone
Journal:  Semin Plast Surg       Date:  2022-08-04       Impact factor: 2.195

Review 5.  Advancements in Regenerative Strategies Through the Continuum of Burn Care.

Authors:  Randolph Stone Ii; Shanmugasundaram Natesan; Christine J Kowalczewski; Lauren H Mangum; Nicholas E Clay; Ryan M Clohessy; Anders H Carlsson; David H Tassin; Rodney K Chan; Julie A Rizzo; Robert J Christy
Journal:  Front Pharmacol       Date:  2018-07-09       Impact factor: 5.810

6.  Limitations to the use of bromelain-based enzymatic debridement (NexoBrid®) for treating diabetic foot burns: a case series of disappointing results.

Authors:  Juan Enrique Berner; Dejan Keckes; Matthew Pywell; Baljit Dheansa
Journal:  Scars Burn Heal       Date:  2018-12-05

7.  Successful treatment of mixed depth flame burns using enzymatic debridement with Nexobrid™ in a patient with aggressive systemic sclerosis (scleroderma).

Authors:  Neil Wickham; K Skaria Alexander; Anthony Fletcher; Ciaran O'Boyle
Journal:  Scars Burn Heal       Date:  2019-01-14

8.  The role of enzymatic debridement in burn care in the COVID-19 pandemic. Commentary by the Italian Society of Burn Surgery (SIUST).

Authors:  Rosario Ranno; Michelangelo Vestita; Pasquale Verrienti; Davide Melandri; Giuseppe Perniciaro; Franz Wilhelm Baruffaldi Preis; Roberto D'Alessio; Giovanni Alessandro; Edoardo Caleffi; Antonio Di Lonardo; Paolo Palombo; Maria Alma Posadinu; Maurizio Stella; Bruno Azzena; Maurizio Governa; Giuseppe Giudice
Journal:  Burns       Date:  2020-04-24       Impact factor: 2.744

Review 9.  Current Therapeutic Strategies in Diabetic Foot Ulcers.

Authors:  Aurelio Perez-Favila; Margarita L Martinez-Fierro; Jessica G Rodriguez-Lazalde; Miguel A Cid-Baez; Michelle de J Zamudio-Osuna; Ma Del Rosario Martinez-Blanco; Fabiana E Mollinedo-Montaño; Iram P Rodriguez-Sanchez; Rodrigo Castañeda-Miranda; Idalia Garza-Veloz
Journal:  Medicina (Kaunas)       Date:  2019-10-25       Impact factor: 2.430

10.  Historical Perspectives on the Development of Current Standards of Care for Enzymatic Debridement.

Authors:  Wolfram Heitzmann; Paul Christian Fuchs; Jennifer Lynn Schiefer
Journal:  Medicina (Kaunas)       Date:  2020-12-17       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.